Health
Synairgen’s SNG001 advances into phase 3 COVID-19 trial – PMLiVE
UK biotech had initially been testing drug for COPD and asthma
Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing.
SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls the body’s antiviral response.
Initially, Synairgen had been evaluating the drug as a treatment for COPD and asthma, although its focus has now shifted to investigating…
-
Business20 hours ago1 Australian stock you’ll probably kick yourself for not owning a decade from now
-
Business19 hours agoIs this the best ASX ETF to diversify your portfolio with?
-
Noosa News12 hours agoPeregian Square revitalised | Noosa Today
-
General19 hours agoUsman Khawaja describes Perth Stadium pitch for first Ashes Test as ‘piece of shit’